NCT05259696 · STUDY IN CONTEXT

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Number of participants who experienced an adverse events (AEs) or a serious adverse event (SAE)

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-gastroesophageal-junction-carcinoma
nct id: NCT05259696
trial label: Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 1
harms Count: 6
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-gastroesophageal-junction-carcinoma
nct id
NCT05259696
outcome key
om-0000
source section id
NCT05259696-om-0000
source outcome index
0
endpoint
Number of Participants Who Experienced AEs or SAEs
endpoint definition
Number of participants who experienced an adverse events (AEs) or a serious adverse event (SAE)
time origin
15 Months
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-gastroesophageal-junction-carcinoma
nct id
NCT05259696
outcome key
om-0000
arm key
OG000
arm label
E-602 1 mg/kg
regimen
Participants received 1 mg/kg E-602 monotherapy administered weekly via IV infusion.
analyzed count
5
analyzed unit
Participants
is comparator
Source null
source pointer
NCT05259696-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-gastroesophageal-junction-carcinoma
nct id
NCT05259696
outcome key
om-0000
arm key
OG001
arm label
E-602 3 mg/kg
regimen
Participants received 3 mg/kg E-602 monotherapy administered weekly via IV infusion.
analyzed count
4
analyzed unit
Participants
is comparator
Source null
source pointer
NCT05259696-om-0000#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-gastroesophageal-junction-carcinoma
nct id
NCT05259696
outcome key
om-0000
arm key
OG002
arm label
E-602 10 mg/kg
regimen
Participants received 10 mg/kg E-602 monotherapy administered weekly via IV infusion.
analyzed count
9
analyzed unit
Participants
is comparator
Source null
source pointer
NCT05259696-om-0000#groups/OG002
release id
clinical-indications-draft-1
disease state id
ds-gastroesophageal-junction-carcinoma
nct id
NCT05259696
outcome key
om-0000
arm key
OG003
arm label
E-602 20 mg/kg
regimen
Participants received 20 mg/kg E-602 monotherapy administered weekly via IV infusion.
analyzed count
15
analyzed unit
Participants
is comparator
Source null
source pointer
NCT05259696-om-0000#groups/OG003
release id
clinical-indications-draft-1
disease state id
ds-gastroesophageal-junction-carcinoma
nct id
NCT05259696
outcome key
om-0000
arm key
OG004
arm label
E-602 30 mg/kg
regimen
Participants received 30 mg/kg E-602 monotherapy administered weekly via IV infusion.
analyzed count
15
analyzed unit
Participants
is comparator
Source null
source pointer
NCT05259696-om-0000#groups/OG004
release id
clinical-indications-draft-1
disease state id
ds-gastroesophageal-junction-carcinoma
nct id
NCT05259696
outcome key
om-0000
arm key
OG005
arm label
E-602 20 mg/kg in Combination With Cemiplimab
regimen
Participants received 20 mg/kg E-602 monotherapy administered weekly via IV infusion. They also received 350 mg cemiplimab administered every 3 weeks via IV infusion.
analyzed count
21
analyzed unit
Participants
is comparator
Source null
source pointer
NCT05259696-om-0000#groups/OG005

harms

release id
clinical-indications-draft-1
disease state id
ds-gastroesophageal-junction-carcinoma
nct id
NCT05259696
harm key
EG000
source section id
NCT05259696-ae
event group key
EG000
event group label
E-602 1 mg/kg
serious affected
3
serious at risk
5
other affected
5
other at risk
5
frequency threshold
5
collection period
Adverse events were collected through the treatment period, up to 12 months, and up to 3 months after treatment discontinuation.
event definition
Adverse Events were graded using CTCAE v5.0
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-gastroesophageal-junction-carcinoma
nct id
NCT05259696
harm key
EG001
source section id
NCT05259696-ae
event group key
EG001
event group label
E-602 3 mg/kg
serious affected
1
serious at risk
4
other affected
4
other at risk
4
frequency threshold
5
collection period
Adverse events were collected through the treatment period, up to 12 months, and up to 3 months after treatment discontinuation.
event definition
Adverse Events were graded using CTCAE v5.0
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-gastroesophageal-junction-carcinoma
nct id
NCT05259696
harm key
EG002
source section id
NCT05259696-ae
event group key
EG002
event group label
E-602 10 mg/kg
serious affected
1
serious at risk
9
other affected
8
other at risk
9
frequency threshold
5
collection period
Adverse events were collected through the treatment period, up to 12 months, and up to 3 months after treatment discontinuation.
event definition
Adverse Events were graded using CTCAE v5.0
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-gastroesophageal-junction-carcinoma
nct id
NCT05259696
harm key
EG003
source section id
NCT05259696-ae
event group key
EG003
event group label
E-602 20 mg/kg
serious affected
6
serious at risk
15
other affected
15
other at risk
15
frequency threshold
5
collection period
Adverse events were collected through the treatment period, up to 12 months, and up to 3 months after treatment discontinuation.
event definition
Adverse Events were graded using CTCAE v5.0
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-gastroesophageal-junction-carcinoma
nct id
NCT05259696
harm key
EG004
source section id
NCT05259696-ae
event group key
EG004
event group label
E-602 30 mg/kg
serious affected
5
serious at risk
15
other affected
15
other at risk
15
frequency threshold
5
collection period
Adverse events were collected through the treatment period, up to 12 months, and up to 3 months after treatment discontinuation.
event definition
Adverse Events were graded using CTCAE v5.0
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-gastroesophageal-junction-carcinoma
nct id
NCT05259696
harm key
EG005
source section id
NCT05259696-ae
event group key
EG005
event group label
E-602 20 mg/kg in Combination With Cemiplimab
serious affected
5
serious at risk
21
other affected
20
other at risk
21
frequency threshold
5
collection period
Adverse events were collected through the treatment period, up to 12 months, and up to 3 months after treatment discontinuation.
event definition
Adverse Events were graded using CTCAE v5.0
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice